Tracked for
Impact Factor
Indexed in
Scopus
22 days
Time to First Decision

Pharmacoepidemiology, Volume 3, Issue 2

2024 June - 4 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (4)

Select all

Brief Report

2 Citations

2,450 Views

10 Pages

A Retrospective Analysis of the Clinical Effectiveness of Tigecycline in the Treatment of Clostridioides difficile-Associated Diarrhea

Herman Joseph Johannesmeyer,
Luiza Baloyan and
Kristica Kolyouthapong

Pharmacoepidemiology2024, 3(2), 231-240;https://doi.org/10.3390/pharma3020015

13 June 2024

Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in the United States. Tigecycline has been proposed as a potential treatment for CDI, though limited clinical data exist to support this practice. The objective of t...

Full Article

Communication

1 Citations

1,862 Views

8 Pages

Ocular Chloramphenicol Exposure in Early Childhood in Aotearoa/New Zealand

Isabella M. Y. Cheung,
Simon Horsburgh,
Ewan Smith,
Samantha Simkin and
Akilesh Gokul

Pharmacoepidemiology2024, 3(2), 223-230;https://doi.org/10.3390/pharma3020014

14 May 2024

Background: The paediatric use of ophthalmic chloramphenicol in New Zealand (NZ) is relatively high; however, little more is known about its utilisation, including whether this is equitable. This study aimed to describe chloramphenicol utilisation in...

Full Article

Review

10 Citations

11,403 Views

15 Pages

Adverse Drug Reactions in Multimorbid Older People Exposed to Polypharmacy: Epidemiology and Prevention

Siobhán McGettigan,
Denis Curtin and
Denis O’Mahony

Pharmacoepidemiology2024, 3(2), 208-222;https://doi.org/10.3390/pharma3020013

30 April 2024

Adverse drug reactions (ADRs) are frequent and represent a significant healthcare burden. ADRs are a potentially avoidable contributor to excess unscheduled hospital admissions, higher morbidity, mortality, and healthcare costs. The objective of this...

Full Article

Article

2,465 Views

10 Pages

Association of Receipt of Opioid Prescription for Acute Post-Delivery Pain Management with Buprenorphine Discontinuation among Postpartum People with Opioid Use Disorder

Taylor N. Hallet,
David T. Zhu,
Hannah Shadowen,
Lillia Thumma,
Madison M. Marcus,
Amy Salisbury and
Caitlin E. Martin

Pharmacoepidemiology2024, 3(2), 198-207;https://doi.org/10.3390/pharma3020012

16 April 2024

Buprenorphine is a safe and effective medication to treat opioid use disorder (OUD) in pregnant patients and is intended to be continued throughout pregnancy, delivery, and at least the one-year postpartum period. However, delivery often involves the...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Pharmacoepidemiology - ISSN 2813-0618

Imprint

Download Flyer